* We welcome and encourage multiple proposals from each institution. *
Modeled after its US programs, this scholar award provides UK researchers with a unique opportunity for funding and personalized discovery and development support to advance promising research into novel treatments for rare disease. The award includes:
- Two-year grant
- £100,000 guaranteed, opportunity to qualify for an additional £400,000
- Drug development expertise and project management support
- A personalized team of drug developers and project manager for each award recipient
- Expert business, commercialization, and clinical development advice
- Regulatory assistance
- Intellectual property (IP) review and advice
- Assistance identifying and securing additional financial support based on project needs
Fund for Cures UK, Ltd. is Harrington Discovery Institute's UK entity and is the granting organization for this program.
Join our emailing list to become a part of our community and receive periodic communications about grant funding opportunities, as well as news and updates.
- MD or PhD (or equivalent)
- Faculty position at an accredited academic medical center, university or research institution in the United Kingdom, and conduct the majority of his/her/their research at that institution. Senior post-docs will also be considered.
- A project must have a single Principal Investigator (PI), who is responsible for project oversight and financial management. The PI may engage collaborators, core labs or commercial CROs to execute any portion of the project.
- Past recipients of Harrington awards may submit new and distinct proposals, but may not seek additional support for previously funded projects.
Late submissions will not be accepted for any reason, other than issues with the Harrington Discovery Institute’s submission system. Proposals received after the deadline will not be reviewed.
The Harrington UK Rare Disease Scholar award selection committee seeks breakthrough discoveries defined by innovation, creativity and potential for clinical impact. Key considerations include:
- Novel approaches to treat rare diseases (European definition of a rare disease should be applied. Ultra-rare diseases will also be considered).
- Potential to be developed into a commercial program
- Strong intellectual property (IP) or protection strategy
- May be a small molecule, biologic, or other therapeutic modality
- Diagnostics or devices only acceptable as part of a therapeutic development project
- Call Opens for Letters of Intent (LOI)
13 June 2022
- LOI Submission Deadline
18 July 2022
- Full Proposal Deadline for those Invited
10 October 2022
- Announce 2023 Harrington UK Rare Disease Scholars
To be determined
HOW TO APPLY APPLY NOW